Mendus

.Hero-module--bg-image--629a6:before { opacity: 1; background-image: url('/static/e62925564ecb1ec6ce1d956cde68e06b/44759/2026-granddad-child-reading-landscape-1-scaled.jpg'); }

Att förändra hur cancer behandlasVi utforskar hur kraften i kroppens immunsystem kan användas för att förbättra långtidsöverlevnaden för cancerpatienter, samtidigt som hälsan och livskvaliteten bevaras.
Om oss
Intervju
<picture><source type="image/webp" srcSet="/static/3bf5d9a2043ea12a69d4fe6cc8971382/c690a/251121-BTG-4.webp 529w,/static/3bf5d9a2043ea12a69d4fe6cc8971382/7f271/251121-BTG-4.webp 1058w,/static/3bf5d9a2043ea12a69d4fe6cc8971382/1404b/251121-BTG-4.webp 2116w" sizes="(min-width: 2116px) 2116px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 2116px) 2116px, 100vw" decoding="async" loading="lazy" src="/static/3bf5d9a2043ea12a69d4fe6cc8971382/4ea1d/251121-BTG-4.jpg" srcSet="/static/3bf5d9a2043ea12a69d4fe6cc8971382/8abc6/251121-BTG-4.jpg 529w,/static/3bf5d9a2043ea12a69d4fe6cc8971382/25568/251121-BTG-4.jpg 1058w,/static/3bf5d9a2043ea12a69d4fe6cc8971382/4ea1d/251121-BTG-4.jpg 2116w" alt=""/></picture>
Intervju med Professor Bjørn Tore GjertsenLäs intervjun
<picture><source type="image/webp" srcSet="/static/24ce6d328978106f0c88a3a11a7fa494/f0323/Slide2.webp 204w,/static/24ce6d328978106f0c88a3a11a7fa494/d1b85/Slide2.webp 408w,/static/24ce6d328978106f0c88a3a11a7fa494/fa1e9/Slide2.webp 816w" sizes="(min-width: 816px) 816px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 816px) 816px, 100vw" decoding="async" loading="lazy" src="/static/24ce6d328978106f0c88a3a11a7fa494/dd920/Slide2.jpg" srcSet="/static/24ce6d328978106f0c88a3a11a7fa494/bf591/Slide2.jpg 204w,/static/24ce6d328978106f0c88a3a11a7fa494/f93a4/Slide2.jpg 408w,/static/24ce6d328978106f0c88a3a11a7fa494/dd920/Slide2.jpg 816w" alt=""/></picture>
Mendus presenterar data om vididencel vid högriskäggstockscancerLäs mer
<picture><source type="image/webp" srcSet="/static/0c437990ac322664c71b74a26c605b7a/f0323/Slide2.webp 204w,/static/0c437990ac322664c71b74a26c605b7a/d1b85/Slide2.webp 408w,/static/0c437990ac322664c71b74a26c605b7a/fa1e9/Slide2.webp 816w" sizes="(min-width: 816px) 816px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 816px) 816px, 100vw" decoding="async" loading="lazy" src="/static/0c437990ac322664c71b74a26c605b7a/dd920/Slide2.jpg" srcSet="/static/0c437990ac322664c71b74a26c605b7a/bf591/Slide2.jpg 204w,/static/0c437990ac322664c71b74a26c605b7a/f93a4/Slide2.jpg 408w,/static/0c437990ac322664c71b74a26c605b7a/dd920/Slide2.jpg 816w" alt=""/></picture>
Mendus publicerar första kvartalsrapporten för 2026Läs mer
<picture><source type="image/webp" srcSet="/static/390b4701d6f320170ad0f0c40b0ad9e2/f0323/Slide2-4.webp 204w,/static/390b4701d6f320170ad0f0c40b0ad9e2/d1b85/Slide2-4.webp 408w,/static/390b4701d6f320170ad0f0c40b0ad9e2/fa1e9/Slide2-4.webp 816w" sizes="(min-width: 816px) 816px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 816px) 816px, 100vw" decoding="async" loading="lazy" src="/static/390b4701d6f320170ad0f0c40b0ad9e2/dd920/Slide2-4.jpg" srcSet="/static/390b4701d6f320170ad0f0c40b0ad9e2/bf591/Slide2-4.jpg 204w,/static/390b4701d6f320170ad0f0c40b0ad9e2/f93a4/Slide2-4.jpg 408w,/static/390b4701d6f320170ad0f0c40b0ad9e2/dd920/Slide2-4.jpg 816w" alt=""/></picture>
Första patienten rekryterad till VITAL-CML-studienLäs mer
<picture><source type="image/webp" srcSet="/static/914b526cb266632d86921bca9d7e3c8c/f0323/Slide2-3.webp 204w,/static/914b526cb266632d86921bca9d7e3c8c/d1b85/Slide2-3.webp 408w,/static/914b526cb266632d86921bca9d7e3c8c/fa1e9/Slide2-3.webp 816w" sizes="(min-width: 816px) 816px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 816px) 816px, 100vw" decoding="async" loading="lazy" src="/static/914b526cb266632d86921bca9d7e3c8c/dd920/Slide2-3.jpg" srcSet="/static/914b526cb266632d86921bca9d7e3c8c/bf591/Slide2-3.jpg 204w,/static/914b526cb266632d86921bca9d7e3c8c/f93a4/Slide2-3.jpg 408w,/static/914b526cb266632d86921bca9d7e3c8c/dd920/Slide2-3.jpg 816w" alt=""/></picture>
Mendus Publicerar Årsredovisning 2025Läs mer
<picture><source type="image/webp" srcSet="/static/b127668601f47377f56f401f4d46bed2/f0323/Slide2-1.webp 204w,/static/b127668601f47377f56f401f4d46bed2/d1b85/Slide2-1.webp 408w,/static/b127668601f47377f56f401f4d46bed2/fa1e9/Slide2-1.webp 816w" sizes="(min-width: 816px) 816px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 816px) 816px, 100vw" decoding="async" loading="lazy" src="/static/b127668601f47377f56f401f4d46bed2/dd920/Slide2-1.jpg" srcSet="/static/b127668601f47377f56f401f4d46bed2/bf591/Slide2-1.jpg 204w,/static/b127668601f47377f56f401f4d46bed2/f93a4/Slide2-1.jpg 408w,/static/b127668601f47377f56f401f4d46bed2/dd920/Slide2-1.jpg 816w" alt=""/></picture>
Att leva med KML: Solveigs BerättelseLäs intervjun
<picture><source type="image/webp" srcSet="/static/7946d4dc128e6f54a65cfdde357e51d5/eec5b/Whitebox-ONJCRI-Agreement-SWE.webp 306w,/static/7946d4dc128e6f54a65cfdde357e51d5/c01ac/Whitebox-ONJCRI-Agreement-SWE.webp 612w,/static/7946d4dc128e6f54a65cfdde357e51d5/57d26/Whitebox-ONJCRI-Agreement-SWE.webp 1224w" sizes="(min-width: 1224px) 1224px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 1224px) 1224px, 100vw" decoding="async" loading="lazy" src="/static/7946d4dc128e6f54a65cfdde357e51d5/5151d/Whitebox-ONJCRI-Agreement-SWE.jpg" srcSet="/static/7946d4dc128e6f54a65cfdde357e51d5/cfe57/Whitebox-ONJCRI-Agreement-SWE.jpg 306w,/static/7946d4dc128e6f54a65cfdde357e51d5/e53f8/Whitebox-ONJCRI-Agreement-SWE.jpg 612w,/static/7946d4dc128e6f54a65cfdde357e51d5/5151d/Whitebox-ONJCRI-Agreement-SWE.jpg 1224w" alt=""/></picture>
Mendus ingår avtal med Olivia Newton-John Cancer Research InstituteLäs mer
<picture><source type="image/webp" srcSet="/static/cdb2c6222842c5845b82ebd0ecccb4de/f4285/251201-GMP-SWE.webp 167w,/static/cdb2c6222842c5845b82ebd0ecccb4de/2a66e/251201-GMP-SWE.webp 334w,/static/cdb2c6222842c5845b82ebd0ecccb4de/bbca0/251201-GMP-SWE.webp 667w" sizes="(min-width: 667px) 667px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 667px) 667px, 100vw" decoding="async" loading="lazy" src="/static/cdb2c6222842c5845b82ebd0ecccb4de/ce353/251201-GMP-SWE.jpg" srcSet="/static/cdb2c6222842c5845b82ebd0ecccb4de/a06cd/251201-GMP-SWE.jpg 167w,/static/cdb2c6222842c5845b82ebd0ecccb4de/02410/251201-GMP-SWE.jpg 334w,/static/cdb2c6222842c5845b82ebd0ecccb4de/ce353/251201-GMP-SWE.jpg 667w" alt=""/></picture>
PressmeddelandeLäs mer
Intervju
<picture><source type="image/webp" srcSet="/static/3bf5d9a2043ea12a69d4fe6cc8971382/c690a/251121-BTG-4.webp 529w,/static/3bf5d9a2043ea12a69d4fe6cc8971382/7f271/251121-BTG-4.webp 1058w,/static/3bf5d9a2043ea12a69d4fe6cc8971382/1404b/251121-BTG-4.webp 2116w" sizes="(min-width: 2116px) 2116px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 2116px) 2116px, 100vw" decoding="async" loading="lazy" src="/static/3bf5d9a2043ea12a69d4fe6cc8971382/4ea1d/251121-BTG-4.jpg" srcSet="/static/3bf5d9a2043ea12a69d4fe6cc8971382/8abc6/251121-BTG-4.jpg 529w,/static/3bf5d9a2043ea12a69d4fe6cc8971382/25568/251121-BTG-4.jpg 1058w,/static/3bf5d9a2043ea12a69d4fe6cc8971382/4ea1d/251121-BTG-4.jpg 2116w" alt=""/></picture>
Intervju med Professor Bjørn Tore GjertsenLäs intervjun
<picture><source type="image/webp" srcSet="/static/24ce6d328978106f0c88a3a11a7fa494/f0323/Slide2.webp 204w,/static/24ce6d328978106f0c88a3a11a7fa494/d1b85/Slide2.webp 408w,/static/24ce6d328978106f0c88a3a11a7fa494/fa1e9/Slide2.webp 816w" sizes="(min-width: 816px) 816px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 816px) 816px, 100vw" decoding="async" loading="lazy" src="/static/24ce6d328978106f0c88a3a11a7fa494/dd920/Slide2.jpg" srcSet="/static/24ce6d328978106f0c88a3a11a7fa494/bf591/Slide2.jpg 204w,/static/24ce6d328978106f0c88a3a11a7fa494/f93a4/Slide2.jpg 408w,/static/24ce6d328978106f0c88a3a11a7fa494/dd920/Slide2.jpg 816w" alt=""/></picture>
Mendus presenterar data om vididencel vid högriskäggstockscancerLäs mer

<picture><source type="image/webp" srcSet="/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/d7070/Startpage_1-NEW.webp 240w,/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/4ce17/Startpage_1-NEW.webp 480w,/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/95cd0/Startpage_1-NEW.webp 960w" sizes="(min-width: 960px) 960px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 960px) 960px, 100vw" decoding="async" loading="lazy" src="/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/49439/Startpage_1-NEW.jpg" srcSet="/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/ff13b/Startpage_1-NEW.jpg 240w,/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/28e6b/Startpage_1-NEW.jpg 480w,/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/49439/Startpage_1-NEW.jpg 960w" alt=""/></picture>
Att få övertagetIdag är återkommande tumörer den främsta orsaken till cancerrelaterade dödsfall. Vi strävar efter att minska tumöråterfall genom att utnyttja immunsystemet för att agera mot kvarvarande cancerceller.
Hur vi gör

<picture><source type="image/webp" srcSet="/static/bfd9bafcd3660b03f3b72edb150264f7/ecbb3/Startpage_2-1.webp 450w,/static/bfd9bafcd3660b03f3b72edb150264f7/10d3d/Startpage_2-1.webp 900w,/static/bfd9bafcd3660b03f3b72edb150264f7/7d31d/Startpage_2-1.webp 1800w" sizes="(min-width: 1800px) 1800px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 1800px) 1800px, 100vw" decoding="async" loading="lazy" src="/static/bfd9bafcd3660b03f3b72edb150264f7/b37a5/Startpage_2-1.jpg" srcSet="/static/bfd9bafcd3660b03f3b72edb150264f7/ea40c/Startpage_2-1.jpg 450w,/static/bfd9bafcd3660b03f3b72edb150264f7/a3b1e/Startpage_2-1.jpg 900w,/static/bfd9bafcd3660b03f3b72edb150264f7/b37a5/Startpage_2-1.jpg 1800w" alt="&lt;p&gt;Two chemistry laboratory researchers, a young man and a young woman working together in a biology, chemistry research laboratory.= in a university. Focus on the laboratory equipment with the personnel in the background. Photographed in horizontal format.&lt;/p&gt;
"/></picture>
Nya sätt att göra skillnadVi tillämpar vår förståelse av dendritisk cellbiologi för att designa immunterapier mot cancer som stimulerar aktiv immunitet, den enda långvariga formen av immunitet.
Om oss

<picture><source type="image/webp" srcSet="/static/0237bef387e76cffaa6681d16a2b59c4/8cdf4/Startpage_3-1.webp 302w,/static/0237bef387e76cffaa6681d16a2b59c4/39272/Startpage_3-1.webp 603w,/static/0237bef387e76cffaa6681d16a2b59c4/0d01b/Startpage_3-1.webp 1206w" sizes="(min-width: 1206px) 1206px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 1206px) 1206px, 100vw" decoding="async" loading="lazy" src="/static/0237bef387e76cffaa6681d16a2b59c4/e579d/Startpage_3-1.jpg" srcSet="/static/0237bef387e76cffaa6681d16a2b59c4/8f82e/Startpage_3-1.jpg 302w,/static/0237bef387e76cffaa6681d16a2b59c4/d2caf/Startpage_3-1.jpg 603w,/static/0237bef387e76cffaa6681d16a2b59c4/e579d/Startpage_3-1.jpg 1206w" alt="&lt;p&gt;Molecular Structure. Science background. 3D Render&lt;/p&gt;
"/></picture>
Investera i framtidens cancervårdMendus är noterat på NASDAQ Stockholm under tickersymbolen IMMU. Du hittar all relevant information om Mendus-aktien på vår investerarsida.
Investerare

Senaste nyheternaNyheter och Evenemang
Inga hittade artiklar

.FullWidthImage-module--bg-image-mobile--ba5fc.FullWidthImage-module--hide-in-mobile--9cd89:before { opacity: 1; background-image: url('/static/58920a993c01776af52e6d8a69a7452d/60e72/What-we-do_1-mobile.jpg'); }

Hur vi gör